Apogee Therapeutics Inc.
Apogee Therapeutics Announces First Patient Dosed in Phase 2 APEX Trial for Atopic Dermatitis Treatment
Summary
On February 3, 2025, Apogee Therapeutics, Inc. announced the first patient has been dosed in the Part B portion of its Phase 2 APEX clinical trial for APG777, a novel monoclonal antibody targeting IL-13 for the treatment of moderate-to-severe atopic dermatitis (AD). Enrollment in the Part A portion of the trial was completed ahead of schedule with 123 patients enrolled, demonstrating strong interest in the trial. The trial aims to evaluate the efficacy and dosing of APG777, with initial data expected in mid-2025.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement